Science

Scientists Target 'Undruggable' Pancreatic Cancer Protein and Nearly Double Survival

New drug daraxonrasib reduces death risk by 60% in clinical trial, offering hope for patients with one of medicine's deadliest cancers.

Scientists Target 'Undruggable' Pancreatic Cancer Protein and Nearly Double Survival
Read the full reporting at ScienceDaily Top.

Originally reported by ScienceDaily Top.

pancreatic cancer KRAS protein daraxonrasib cancer treatment clinical trial oncology